Interferon gamma Induced Protein 10 (IP-10)
Interferon gamma Induced Protein 10 (IP-10; 10kDa interferon-gamma-induced protein; CXCL10) is induced in a variety of cells in response to IFN-gamma. IP-10 inhibits bone marrow colony formation and angiogenesis, stimulates NK and T cell migration, regulates T cell maturation, and modulates adhesion molecule expression. IP-10 expression has been associated with HIV infection and levels have been shown to be elevated in patients with Alzheimer’s disease.
Swiss-Prot Accession Number: P02778
PublicationsPeripheral lymphocyte signaling pathway deficiencies predict treatment response in first-onset drug-naïve schizophrenia (2022) Santiago G. Lago, Jakub Tomasik, Geertje F. Rees, Nitin Rustogi, Javier Vazquez-Bourgon, Sergi Papiol, Paula Suarez-Pinilla, Benedicto Crespo-Facorro, Sabine Bahn Brain Behavior and Immunity
Utility of urinary cytokine levels as predictors of the immunogenicity and reactogenicity of AS01-adjuvanted hepatitis B vaccine in healthy adults (2022) Wivine Burny, Caroline Herve, Magalie Caubet, Juan Pablo Yazabal, Arnaud M Didierlaurent Vaccine
Muscle damage in systemic sclerosis and CXCL10: The potential therapeutic role of PDE5 inhibition (2021) Corinalesi C, Ross RL, Abignano G, Antinozzi C, Marampon F, di Luigi L, Buch MH, Riccieri V, Lenzi A, Crescioli C, Del Galdo F International Journal of Molecular Sciences
Safety, pharmacokinetics, and efficacy of budigalimab with rovalpituzumab teserine in patients with small cell lung cancer (2021) Calvo E, Spira A, de Miguel M, Kondo S, Gazzah A, Millward M, Prenen H, Rottey S, Warburon L, Alanko T, Cassier PA, Yoh K, Italiano A, Moreno V, Peltola K, Seto T, Toyozawa R, Afar DE, Englert S, Komarnitsky P, Lambert S, Parikh A, Vosganian G, Gao B Cancer Treatment and Research Communities
First-in-human phase 1 study of budigalimab, an anti-PD-1 inhibitor, in patients with non-small cell lung cancer and head and neck squamous cell carcinoma (2021) Italiano A, Cassier PA, Lin CC, Alanko T, Peltola KJ, Gazzah A, Shiah HS, Calvo E, Cervantes A, Roda D, Tosi D, Gao B, Millward M, Warburton L, Tanner M, Englert S, Lambert S, Parikh A, Afar DE, Vosganian G, Moreno V Cancer Immunology, Immunotherapy
Urelumab alone or in combination with rituximab in patients with relapsed or refractory B-cell lymphoma (2020) Timmerman J, Herbaux C, Ribrag V, Zelenetz AD, Houot R, Neelapu SS, Logan T, Lossos IS, Urba W, Salles G, Ramchandren R, Jacobson C, Godwin J, Carpio C, Lathers D, Liu Y, Neely J, Suryawanshi S, Koguchi Y, Levy R American Journal of Hematology
Inflammatory parameters associated with systemic reactogenicity following vaccinatino with adjuvanted hepatitis B vaccines in humans (2019) Burny W, Marchant A, Herve C, Callegaro A, Caubet M, Fissette L, Gheyle L, Legrand C, Ndour C, Tavares Da Silva F, van der Most R, Willems F, Didierlaurent AM, Yarzabal J, ECR-008 study group Vaccine
Early changes in immune, coagulation, and organ function after clinical and experimental polytrauma (2019) Halbgbauer Repositorium der Universität Ulm
Increased serum levels of leptin and insulin in both schizophrenia and major depressive disorder: A cross-disorder proteomics analysis (2019) Cakici N, Bot M, Lamers F, Janssen T, van der Haan L, Bahn S, Penninx BWJH, van Beveren NJM European Neuropsychopharmacology
Dendritic cell immunotherapy followed by cART interruption during HIV-1 infection induces plasma protein markers of cellular immunity and neutrophil recruitment (2018) van den Ham HJ, Cooper J, Tomasik J, Bahn S, Aerts J, Oseterhaus A, Gruters R, Andeweg A PLoS One
Dendritic cell immunotherapy followed by cART interruption during HIV-1 infection induces plasma protein markers of cellular immunity and neutrophil recruitment (2018) van den Ham HJ, Cooper J, Tomasik J, Bahn S, Aerts J, Oseterhaus A, Gruters R, Andeweg A PLoS One
Toxoplasma gondii inactivates human plasmacytoid dendritic cells by functional mimicry of IL-10 (2018) Piotr L, Zhao Y, Singh S, Dai J, Yap GS, Fitzgerald-Bocarsly P The Journal of Immunology
Serum IP-10 levels and increased DPPIV activity are linked to circulating CXCR3+ T cells in cholestatic HCV patients (2018) Rau M, Schmitt J, Berg T, Kremer AE, Stieger B, Spanaus K, Bengsch B, Romero MR, Marin JJ, Keitel V, Klinker H, Tony HP, Mullhaupt B, Geier A PLoS One
A Sputum Proteomic Signature That Associates with Increased Il-1? Levels and Bacterial Exacerbations of COPD (2016) Damera G, Pham T-H, Zhang J, Ward CK, Newbold P, Ranade K, Sethi S Lung
Immunomodulatory Activity of Nivolumab in Metastatic Renal Cell Carcinoma (2016) Choueiri TK, Fishman M, Escudier B, McDermott DF, Drake CG, Kluger HM, Stadler WM, Perez-Gracia JL, McNeel DG, Curti BD, Harrison MR, Plimack ER, Appleman L, Fong L, Albiges L, Cohen LJ, Young TC, Chasalow SD, Ross-MacDonald P, Srivastava S, Jure-Kunkel M, Kurland JF, Simon JS, Sznol M Clinical Cancer Research
Variation in Serum Biomarkers with Sex and Female Hormonal Status: Implications for Clinical Tests (2016) Ramsey JM, Cooper JD, Penninx BWJH, Bahn S Scientific Reports
The Tyrosine Kinase Inhibitors Imatinib and Dasatinib Reduce Myeloid Suppressor Cells and Release Effector Lymphocyte Responses. (2015) Christiansson L, Soderlund S, Mangsbo SM, Hjorth-Hansen H, Höglund M, Markevarn B, Richter J, Stenke L, Mustjoki S, Loskog A, Olsson-Stromberg U. Mol Cancer Ther. 2015 Mar 11. pii: molcanther.0849.2014. [Epub ahead of print]
Biomarker results from a clinical trial of nivolumab in patients (pts) with metastatic renal cell carcinoma (mRCC) (CA209-009): Gene expression, serum profiling for immune markers, and multiplex tissue immunohistochemistry (IHC) (2015) Choueiri TK, Fishman MN, Escudier B, Stadler WM, Chasalow S, Ross-Macdonald P, Jure-Kunkel M, Sznol M, and Simon JS Cancer Res
Predicting therapeutic efficacy of intravenous immunoglobulin (IVIG) in individual patients with relapsing remitting multiple sclerosis (RRMS) by functional genomics (2014) Berger T, Jacob C, Haas J, Ransmayr G, Guger M, Zettl UK, Di Pauli F, Taumberger B, Wietek S, Meuer S, Reindl M, Giese T Journal of Neuroimmunology DOI: 10.1016/j.jneuroim.2014.10.001
CXCL10 antagonism and plasma sDPPIV correlate with increasing liver disease in chronic HCV genotype 4 infected patients (2013) Ragab D, Laird M, Duffy D, Casrouge A, Mamdouh R, Abass A, Shenawy DE, Shebl AM, Elkashef WF, Zalata KR, Kamal M, Esmat G, Bonnard P, Fontanet A, Rafik M, Albert ML Cytokine. 2013 May 7. pii: S1043-4666(13)00181-6
Interleukin 17F Level and Interferon Beta Response in Patients With Multiple Sclerosis (2013) Hartung HP, Steinman L, Goodin DS, Comi G, Cook S, Filippi M, O'Connor P, Jeffery DR, Kappos L, Axtell R, Knappertz V, Bogumil T, Schwenke S, Croze E, Sandbrink R, Pohl C JAMA Neurol. 2013 Aug 1;70(8):1017-21
Characterization of immunologically active drugs in a novel organotypic co-culture model of the human gut and whole blood (2012) Schmohl M, Schneiderhan-Marra N, Baur N, Hefner K, Blum M, Stein GM, Joos TO, Schmolz M Int Immunopharmacol. 2012 Dec;14(4):722-8
Evidence for an antagonist form of the chemokine CXCL10 in patients chronically infected with HCV (2011) Casrouge A, Decalf J, Ahloulay M, Lababidi C, Mansour H, Vallet-Pichard A, Mallet V, Mottez E, Mapes J, Fontanet A, Pol S, Albert ML J Clin Invest. 121: 308-317.
Discrimination of agonist and antagonist forms of CXCL10 in biologic samples (2011) Casrouge A, Bisiaux A, Stephen L, Schmolz M, Mapes J, Pfister C, Pol S, Mallet V, Albert ML Clin Exp Immunol. 2012 Jan;167(1):137-48
Molecular Analyte Profiling of the Early Events and Tissue Conditioning Following Intravesical Bacillus Calmette-Guerin Therapy in Patients With Superficial Bladder Cancer. (2009) Bisiaux A, Thiounn N, Timsit MO, Eladaoui A, Chang HH, Mapes J, Mogenet A, Bresson JL, Prié D, Béchet S, Baron C, Sadorge C, Thomas S, Albert EB, Albert PS, Albert ML J Urol 181: 1571-1580.